Clinical and Biochemical Markers in Early Pregnancy for Prediction of Gestational Diabetes Mellitus

妊娠早期临床和生化标志物对妊娠期糖尿病的预测

阅读:1

Abstract

INTRODUCTION: Gestational Diabetes Mellitus (GDM) is associated with an increased risk of feto-maternal and neonatal complications. Many of these complications can be reduced or eliminated, if GDM can be predicted in early pregnancy. Current risk prediction models lack a strong predictive value. In this study, we aim to evaluate the early trimester maternal parameters for future prediction of GDM. METHODS: In this prospective observational study, we screened 581 consecutive healthy women with singleton pregnancy for GDM during their first antenatal visit. After informed consent, fasting blood samples were collected and stored at -80°C. GDM was diagnosed as per IADPSG criteria. During prospective follow-up, a total of 55 patients developed GDM. A total of 110 age and BMI-matched controls were recruited for comparison. In all women, we measured the Oral Glucose Tolerance test with 75 gm anhydrous glucose, fasting insulin, HbA1c, hsCRP, uric acid, and lipid Profile. HOMA-IR, HOMA-β, and QUICKI were also assessed. RESULTS: The GDM cohort had significantly higher median waist circumference, 2 hr plasma glucose, HbA1c, fasting insulin, HOMA-IR, hsCRP, uric acid, and serum triglyceride levels. Multiple regression analysis revealed HbA1c (OR 5.264; P = 0.007), 2 hr PPG (OR 1.026; P = 0.035), QUICKI (OR 1.057; P = 0.016), uric acid (OR 1.931; P = 0.013) and neutrophil: lymphocyte ratio (OR 1.545; P = 0.008) to be independently associated with GDM outcome with combined area under the curve (AUC) of 0.850, a sensitivity of 72.7%, and a specificity of 87.3%. CONCLUSION: Fasting Insulin, HbA1c, HOMA-IR, hsCRP, and Uric acid levels are significantly increased in early pregnancy in individuals who subsequently develop GDM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。